Key Highlights

  • Tilray (NASDAQ:TLRY) reported first-quarter revenue of USD 257.1 million on October 8, 2026, up 23% year over year but below the estimate of USD 266.3 million, per the company release and calendar data.
  • The revenue miss was USD 9.2 million, or about 3.5% of the estimate, simple arithmetic on two published numbers, which is modest next to the 23% growth the company reported.
  • Earnings per share were a loss of USD 0.32 versus an expected loss of USD 0.18, so Tilray (NASDAQ:TLRY) lost USD 0.14 per share more than analysts forecast.
  • Management reaffirmed fiscal 2027 adjusted EBITDA guidance of USD 68 million to USD 75 million, a signal that it still expects profit growth despite the quarter's shortfall.

The Quarter in Numbers

Tilray (NASDAQ:TLRY) released first-quarter fiscal 2027 results on October 8, 2026. Revenue was USD 257.1 million, up 23% from a year earlier but about USD 9.2 million short of the USD 266.3 million consensus, simple arithmetic. Earnings per share came in at a loss of USD 0.32, compared with an expected loss of USD 0.18. The topics file marks the figures as verified because the earnings calendar data matches the recap. The company kept its fiscal 2027 adjusted EBITDA guidance at USD 68 million to USD 75 million. The file does not explain the cause of the wider loss, so readers should check the release for items such as impairments, interest costs or one-time charges.

Why Growth and a Miss Can Coexist

A revenue miss with strong growth means expectations were higher than the actual result, not that sales fell. Cannabis and beverage companies often face pricing pressure, changing product mix and regulatory uncertainty, which can make quarterly results hard to forecast. Analysts build consensus numbers from company guidance and recent trends, so even a good quarter can disappoint if the forecast was ambitious. Adjusted EBITDA strips out interest, taxes, depreciation and certain items, so it shows operating performance but can hide real costs. Tilray (NASDAQ:TLRY) reaffirmed that measure, which suggests management sees the loss as less important than cash operating profit, though the gap between the two deserves scrutiny.

Risks and What to Watch

Risks include a persistent gap between adjusted and reported results, regulatory changes in cannabis markets, debt costs and competition in beverages and wellness products. A 10-year Treasury yield near 5.35% raises financing costs for companies that carry debt. Investors should look at the cash flow statement, segment margins and any guidance for the second quarter. The Federal Reserve meets October 27 and 28, 2026, and the consumer sector has seen mixed data. Tilray (NASDAQ:TLRY) has repeatedly drawn attention in cannabis coverage, so comparisons with prior quarters are important. The October 8 stock reaction was not captured in the information reviewed and should be checked before publication.

Where Things Stand

Tilray missed because revenue of USD 257.1 million fell short of the USD 266.3 million estimate and the loss of USD 0.32 per share was wider than the expected USD 0.18, even though sales grew 23%. Tilray (NASDAQ:TLRY) kept its adjusted EBITDA guidance, which supports a view that operations are on track. The balance of evidence is mixed: solid growth, a modest revenue miss and a larger bottom-line gap. The next catalyst is the second-quarter report and cannabis regulation news.